Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071552 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL18023468 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL27586328 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL13241883 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL2126624 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL13241886 | 0.98 | FAAH (0.64) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL22746115 | 0.94 | FAAH (0.52) | FAAHHSP90AA1DNM1RECQLCASP2 | |
| SCHEMBL11505724 | 0.91 | RECQL (0.58) | FAAHHSP90AA1DNM1RECQLMEN1 | |
| SCHEMBL17049333 | 0.85 | — | — | |
| SCHEMBL8639742 | 0.82 | TSHR (0.46) | FAAHRECQLCASP2CNR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354931-B2 | Treating obstructive airway disorders using nontoxic drug | ROCHE PALO ALTO LLC (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
| EP-1442032-B1 | HETEROCYCLIC RETINOID COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20050049238-A1 | Heterocyclic retinoid compounds | KLAUS MICHAEL (DE) | 2005-03-03 | — | — | US | disclosed |
| US-6818652-B2 | THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-16 | — | — | US | disclosed |
| EP-1442032-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| US-20030158178-A1 | Heterocyclic retinoid compounds | SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| WO-2003037882-A1 | HETEROCYCLIC RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | CNR1, CNR2, GPR55 | FAAH 64/4885HSP90AA1 3835/4885DNM1 794/4885 |
| US-20050049238-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | FAAH 2378/4885HSP90AA1 3317/4885DNM1 1589/4885 |
| US-20030158178-A1 | Heterocyclic retinoid compounds | RARG, RXRG, RXRA | FAAH 2378/4885HSP90AA1 3317/4885DNM1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.